Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase
UMass Chan Affiliations
Department of PathologyDepartment of Medicine, Division of Hematology Oncology
Document Type
Journal ArticlePublication Date
2021-07-09Metadata
Show full item recordAbstract
In summary, we show rapid and deep remission induced by blinatumomab in CD19(+) blast phase CML. Clinicians may consider the use of bispecific T-cell engager therapy as a bridge to transplant. Additional studies are needed before expanding the US Food and Drug Administration indication of blinatumomab to include lymphoid blast phase CML.Source
Patel SA, Bledsoe JR, Higgins AW, Hutchinson L, Gerber JM. Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase. JCO Precis Oncol. 2021 Jul 9;5:PO.21.00039. doi: 10.1200/PO.21.00039. PMID: 34409243; PMCID: PMC8367045. Link to article on publisher's site
DOI
10.1200/PO.21.00039Permanent Link to this Item
http://hdl.handle.net/20.500.14038/42044PubMed ID
34409243Related Resources
Rights
Copyright © 2021 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/Distribution License
http://creativecommons.org/licenses/by-nc-nd/4.0/Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2021 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/